Neptune and Acasti Welcome Professor William Harris to Acasti's Scientific Advisory Board

Neptune Technologies & Bioressources Inc. ("Neptune") (Nasdaq:NEPT) (TSX-V:NTB) and Acasti Pharma Inc. ("Acasti") are pleased to announce a further expansion of Acasti's Scientific Advisory Board (SAB) by welcoming Dr. William S. Harris, PhD, who is joining the current renowned members Pr S Nissen (Cleveland Clinic), Pr Thomas G. Hartman (Rutgers University Center), Dr. Magdy M. Abdel-Malik (Quaestio Global Partners).

Dr. Harris, an internationally recognized expert on omega-3 fatty acids, is a PhD in Nutritional Biochemistry, Research Professor (Departments of Internal Medicine, University of South Dakota), Senior Scientist and Director at the Cardiovascular Health Research Center (Sandford Research/USD Sioux Falls). Over the last 30 years, Dr. Harris has published over 180 scientific articles on omega-3s, including his revolutionary work which first proposed the Omega-3 Index as a cardiovascular risk factor. He has also co-authored the America Heart Association's scientific landmark statement, "Fish Consumption, Fish Oil, Omega-3 Fatty Acids and Cardiovascular Disease," published in 2002 in the journal Circulation.  He has been the principal investigator on 5 omega-3 related National Institutes of Health (NIH) grants, and the co-developer of the Omega-3 Index as a new risk factor for cardiovascular and neurocognitive disease in Framingham and the Women's Health Initiative.

"Acasti is delighted to welcome Dr. Harris, as an active member of our SAB. He brings valuable expertise in the field of omega-3 research in cardiometabolic and neurodegenerative conditions," said Dr. Tina Sampalis, President of Acasti Pharma Inc. "Given the positive feedback we have received from the Center for Drug Evaluation and Research, Dr. Harris' participation in the SAB is coming at the most opportune time. We are all very excited and looking forward to benefiting from the advice of our SAB members who are internationally recognized amongst the best in the cardiovascular field," she added.

"I am excited to join the Acasti SAB, as I am particularly impressed with the emphasis that the company puts into research in qualifying the role and function of omega-3's in the management of dyslipidemia and cardiovascular risks," said Dr. Harris. "It is exciting to be involved in the initial development steps of what may prove to be the next omega-3 lipid modulator," he added.

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets.

About NeuroBioPharm 

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements"  within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such  forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause  the actual results of the Company to be materially different from historical results or from any future results expressed or  implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties,  readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates,"  "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject  generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the  Securities and Exchange Commission and the Canadian securities commissions.

 

CONTACT:  Neptune Technologies & Bioressources Inc. 

          Andre Godin, V.P. Administration and Finance
          +1 450.687.2262
          [e-mail]
          www.neptunebiotech.com
          Acasti Pharma Inc.
          Dr. Tina Sampalis, President
          +1 450.686.4555
          [e-mail]
          www.acastipharma.com